AGN - Allergan plc

NYSE - NYSE Delayed Price. Currency in USD
188.34
+0.07 (+0.04%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close188.27
Open188.30
Bid158.67 x 800
Ask0.00 x 800
Day's Range187.95 - 190.41
52 Week Range114.27 - 190.41
Volume2992787
Avg. Volume2,179,382
Market Cap62B
Beta (5Y Monthly)1.64
PE Ratio (TTM)N/A
EPS (TTM)-27.98
Earnings DateJan 27, 2020 - Jan 31, 2020
Forward Dividend & Yield2.96 (1.59%)
Ex-Dividend Date2019-11-12
1y Target Est187.64
  • PR Newswire

    BOTOX® (onabotulinumtoxinA) Celebrates 30 Years of Endless Innovation

    Allergan plc (NYSE: AGN) is commemorating today the beginning of the 30th anniversary celebration for BOTOX® this year with the ringing of the New York Stock Exchange opening bell. Over the past 30 years, more than 100 million vials of BOTOX® and BOTOX® Cosmetic have been manufactured worldwide, providing a trusted and effective treatment option for various therapeutic and aesthetic uses. With two additional U.S. Food and Drug Administration (FDA) approvals this year for therapeutic indications of pediatric upper limb spasticity and pediatric lower limb spasticity, excluding spasticity caused by cerebral palsy, BOTOX® and BOTOX® Cosmetic now proudly hold 14 therapeutic and aesthetic indications combined, reinforcing its leadership in neurotoxin science.

  • Biotech Stocks Burn A Hole In Big Pharma's Pocket; Look For More Mergers In 2020
    Investor's Business Daily

    Biotech Stocks Burn A Hole In Big Pharma's Pocket; Look For More Mergers In 2020

    Mergers and acquisitions have lit up biotech stocks, and the hot pace shows no sign of slowing in 2020. Gene therapy and oncology companies are targets.

  • 5 Cheap Dividend Stocks With High Yields And Annual Increases
    InvestorPlace

    5 Cheap Dividend Stocks With High Yields And Annual Increases

    When writing this article, I was looking for an ideal list of dividend-paying stocks that consistently raise their dividends each year. In addition, the dividend yields have to be higher than average. I used a cutoff of 4 to 6% dividend yield.This is much higher than the S&P 500, with its dividend yield of 1.8%. So picking these stocks has a good chance of appreciation.The stocks also have to be cheap. The price-to-earnings ratio hurdle to make my list is 11 times or lower. This is significantly lower than most stocks trading today. For example, the S&P 500 P/E ratio is 23.8 times earnings. On a forward basis, it is slightly below 20x. So my cutoff is almost 50% to 60% of the market average.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * The 10 Worst Dividend Stocks of the Decade Lastly, the company has to be able to afford the dividends. Earnings per share must be higher than the dividend per share.Even with as strict as all that may sound, I still found five stocks that met these criteria in spades. You might consider investing in them. Dividend Stocks to Buy: AT&T (T)Dividend Yield: 5.3%Price-to-Earnings Ratio: 10.8xAverage Dividend Growth Over 5 Years: 2%Source: Mark R. Hake AT&T (NYSE:T) has consistently raised its dividends to shareholders each year. You can see this in the chart I prepared, at right. Dividends per share are growing consistently by 2% or higher each year over the past three to five years.In addition, AT&T is very cheap compared to its earnings per share. The P/E ratio is below 11x.AT&T purchased Time Warner a little over a year ago and is still in the process of integrating the company. Analysts expect earnings to grow by 2.2% in 2020. Moreover, this is also the same amount by which dividends are expected to grow next year.T stock is expected to begin buying back shares on a larger scale. I recently wrote an article about this which you can read here. Moreover, earnings cover T stock dividend very well. The $2.05 dividend rate represents just 57% of its expected $3.55 earnings per share. AbbVie (ABBV)Dividend Yield: 5.3%Price-to-Earnings Ratio: 9.9xAverage Dividend Growth Over 5 years: 21%AbbVie is a $128 billion market value drug manufacturing company. It has consistently raised its dividend over the past five years. You can see this in the chart I have prepared. On average dividends have increased by 21% per year.Source: Mark R. Hake In addition, ABBV stock is very cheap. For example, International Business Machines (NYSE:IBM) stock trades for less than 10 times earnings. In 2020, expected earnings of $9.91 per share put ABBV stock at a P/E of 8.75 times.Abbie made a cash and stock bid for Allergan (NYSE:AGN) in late June 2019. AGN is a $61 billion market cap U.K./U.S. drug company. The deal is expected to close in early 2020. AbbVie claims the deal will significantly increase shareholder value.As it stands, the dividend per share for ABBV stock is well covered by its earnings. The annual $4.72 dividend per share represents just 53% of expected earnings of $8.93 per share. * 7 Sinfully Good Casino Stocks That Could Win the Jackpot in 2020 In sum, ABBV stock looks like a good cheap, high-yield and consistent dividend-paying stock worth buying. Dividend Stocks to Buy: Harley-Davidson (HOG)Dividend Yield: 3.9%Price-to-Earnings Ratio: 11.6xAverage Dividend Growth Over 5 Years: 11.99%Harley-Davidson (NYSE:HOG) stock has a very nice dividend yield of 3.9%. The company has had a rough few years from EU and China tariffs. Nevertheless, HOG has paid consistently higher dividends, as can be seen in the chart. Its average dividend growth has been 12% over the past five years.Source: Mark R. Hake HOG stock presently trades on 11.6 times earnings. The company is experiencing lower earnings from the tariffs and lower bike sales as a result. Nevertheless, it has reduced its costs. Revenue next year is expected to be slightly higher than this year.Earnings for 2020 are expected to be $3.55 per share by analysts covered by Seeking Alpha. That puts HOG stock at less than 11x earnings.The dividend per share of $1.50 is well covered by expected earnings. Once the tariffs are lifted, HOG stock has a good chance of increasing earnings and dividends dramatically.Meanwhile, the dividend yield of almost 4% is a good inducement for investors to wait for things to turn around for Harley-Davidson. International Business Machines (IBM)Dividend Yield: 4.8%Price-to-Earnings: 10.6xAverage Dividend Growth 5 Years: 10.91%IBM has consistently raised its dividend per share over the past 5 years. Its average dividend growth has been stellar at 10.9%. You can see this in the chart at the right.Source: Mark R. Hake In addition, IBM is very cheap. It trades at just 10.6 times earnings. In 2020 EPS is expected to be $13.31 per share, according to Seeking Alpha. This puts IBM stock on just 10x forward earnings.Moreover, IBM's $6.48 dividend per share is just over 50% of the EPS of $12.80 or so expected this year. As a result, you can see the earnings well cover the dividend.I have written several articles on IBM and its push into the hybrid cloud space now that it fully owns Red Hat. IBM paid $34 billion for that acquisition, which closed in early July 2019. IBN believes the hybrid cloud market represents a $1.2 trillion opportunity over the next decade. Most companies will need to move their operations onto the cloud over that period. * 7 Earnings Reports to Watch Next Week This bodes well for IBM over the long run. With its 4.8% dividend yield, IBM stock will pay investors to investors to wait for earnings to take advantage of the expected spike from hybrid cloud growth. Kohl's Corp (KSS)Dividend Yield: 5.5%Price-to-Earnings: 10.3xAverage Dividend Growth 5 Years: 11.4%Kohl's (NYSE:KSS), the department store chain, can catch your eye with a very nice dividend yield of 5.5%. Moreover, KSS has increased its dividend annually on average 11.4% over the past five years.EPS is expected to be $4.77 this year. Therefore KSS's earnings well cover the dividends. Dividends take up just 56% of earnings. In addition, next year EPS is expected to be roughly flat with this year, according to Seeking Alpha.KSS stock trades for about 10 times earnings. KSS stock is very cheap at these prices. For example, several reasons for this relate to tariff headwinds and customers' increasing preference to shop online. Its recent deal to take in Amazon returns will help drive traffic to its physical stores.I believe that Kohl's will be a winner in the omnichannel sales space. At this price, which is very cheap, the dividend pays investors very well to wait for the company to grow earnings.As of this writing, Mark Hake, CFA does not hold a position in any of the aforementioned securities. Mark Hake runs the Total Yield Value Guide which you can review here. The Guide focuses on high total yield value stocks. This includes both high dividend and buyback yield stocks. In addition, subscribers a two-week free trial. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * These 7 S&P 500 Stocks Will Deliver a Repeat Performance in the Next Decade * 7 Tech Stocks to Stuff Your Stocking With * 7 Sinfully Good Casino Stocks That Could Win the Jackpot in 2020 The post 5 Cheap Dividend Stocks With High Yields And Annual Increases appeared first on InvestorPlace.

  • Barrons.com

    Walgreens, AbbVie, and 3 Other Dividend Aristocrat Stocks That Have Lagged the Market This Year

    The S&P 500 Dividend Aristocrats—the companies which have raised their dividends for at least 25 straight years—are known for their durability, especially in a difficult market. For example, in last year’s tumultuous fourth quarter, with the S&P 500 down 13.5%, the Aristocrats fell 8.6%. 2019 has hardly been tough for stocks, with the S&P 500 having returned about 26%.

  • AbbVie's 2019 Points to the End of the Efficient Market Thesis - Cramer

    Jim Cramer sees the market's reaction to AbbVie's purchase of Allergan as an example of its move away from valuing fundamentals and instead getting bogged down in the noise.

  • MarketWatch

    Exicure shares rise on immuno-oncology trial

    Shares of Exicure Inc. gained 6% in premarket trading after it said that it will start enrolling patients in a Phase 2 trial for the biotech's experimental immuno-oncology drug. Exicure last month announced a deal with Allergan in which the companies will develop treatments for hair loss disorders. Exicure stock is down 15% year-to-date, while the S&P 500 is up about 25%.

  • Biotech ETFs Hit New Highs on Deal Activities
    Zacks

    Biotech ETFs Hit New Highs on Deal Activities

    Following the new deals in the healthcare space, a few biotech ETFs hit new highs.

  • John Paulson's Top 5 Buys in the 3rd Quarter
    GuruFocus.com

    John Paulson's Top 5 Buys in the 3rd Quarter

    Merger arbitrage guru releases portfolio Continue reading...

  • Allergan (AGN) Up 4.5% Since Last Earnings Report: Can It Continue?
    Zacks

    Allergan (AGN) Up 4.5% Since Last Earnings Report: Can It Continue?

    Allergan (AGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • PR Newswire

    Allergan Announces Positive Phase 3 ACHIEVE I Trial Results for Ubrogepant Published in The New England Journal of Medicine

    Allergan plc (NYSE: AGN) today announced that positive results from ACHIEVE I (UBR-MD-01), a robust Phase 3 clinical trial evaluating the efficacy, safety and tolerability of ubrogepant, have been published in the December 5th issue of The New England Journal of Medicine (NEJM). The data from this second published pivotal trial reinforced that the acute treatment of migraine with ubrogepant, compared with placebo, led to significantly greater rates of pain freedom and freedom from the most bothersome migraine-associated symptom at two hours with both the 50 mg and 100 mg doses. If FDA-approved, ubrogepant would be the first available and approved small molecule, oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the acute treatment of migraine.

  • AstraZeneca Sells Schizophrenia Drug Rights in US and Canada
    Zacks

    AstraZeneca Sells Schizophrenia Drug Rights in US and Canada

    AstraZeneca (AZN) divests commercial rights to its schizophrenia and bipolar disorder medicines Seroquel/Seroquel XR in the United States and Canada to Cheplapharm Arzneimittel GmbH.

  • AbbVie Stock Is Poised To Become A Top 5 Pharma — But Should You Buy It?
    Investor's Business Daily

    AbbVie Stock Is Poised To Become A Top 5 Pharma — But Should You Buy It?

    AbbVie stock fell on its $63 billion plan to acquire Botox-maker Allergan, which helps the pharmaceutical company diversify as Humira patents expire. So, is ABBV stock a buy right now?

  • Money in Medicine: These drug and device companies paid the most to D.C. doctors in 2018​
    American City Business Journals

    Money in Medicine: These drug and device companies paid the most to D.C. doctors in 2018​

    The drug makers and medical device firms that made the most payments to District physicians and health systems last year include a handful of industry giants with deep local ties.

  • PR Newswire

    Announcement under the Irish Takeover Rules: Relevant Securities in Issue - November 29, 2019

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

  • Private Capital Exits Allergan, Universal Health Services
    GuruFocus.com

    Private Capital Exits Allergan, Universal Health Services

    Firm's largest sales of the 3rd quarter. Continue reading...

  • NASH Scorecard Year to Date: The Winners and the Losers
    Zacks

    NASH Scorecard Year to Date: The Winners and the Losers

    NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.

  • Here is the 23rd Most Popular Stock Among 752 Hedge Funds
    Insider Monkey

    Here is the 23rd Most Popular Stock Among 752 Hedge Funds

    Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the third quarter. You can find articles about an individual hedge fund's trades on numerous financial […]

  • 3 Stocks for Value Investors to Buy as Market Reaches New High
    Zacks

    3 Stocks for Value Investors to Buy as Market Reaches New High

    The stock market closed at a record high today as the DJIA rose over 42 points and the S&P 500 gained 0.4%.

  • TEST Business Wire Releases

    National Consumer Rights Law Firm FeganScott Files Second, Expanded Class-Action Lawsuit Against Allergan

    Allergan, the manufacturers of BIOCELL textured "gummy" breast implants, is the target of a second proposed national class-action lawsuit by consumer-rights law firm FeganScott. The expanded complaint, which broadens the range of the allegedly defective products covered by the suit, claims that although the FDA issued a recall for Allergan’s BIOCELL products, the company has no plans to provide medical monitoring for individuals at risk of developing breast implant-associated anaplastic large cell lymphoma (BIA-ALCL).

  • Alkermes Submits NDA to FDA for Schizophrenia & Bipolar I Drug
    Zacks

    Alkermes Submits NDA to FDA for Schizophrenia & Bipolar I Drug

    Alkermes (ALKS) submits NDA to the FDA seeking approval of ALKS 3831 for the treatment of schizophrenia and bipolar I disorder.

  • Benzinga

    The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Allergan ...

  • Mason Hawkins' Southeastern Buys 1, Sells 2 in 3rd Quarter
    GuruFocus.com

    Mason Hawkins' Southeastern Buys 1, Sells 2 in 3rd Quarter

    Longleaf Partners Funds manager invests in Venator Materials Continue reading...

  • PR Newswire

    Allergan Announces Positive Phase 3 ACHIEVE II Trial Results for Ubrogepant Published in The Journal of the American Medical Association

    DUBLIN, Nov. 19, 2019 /PRNewswire/ -- Allergan plc (AGN) today announced that positive results from ACHIEVE II (UBR-MD-02), a pivotal Phase 3 clinical trial evaluating the efficacy, safety and tolerability of ubrogepant, have been published in the November 19th issue of The Journal of the American Medical Association (JAMA). If approved, ubrogepant would potentially be the first FDA-approved small molecule, oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the acute treatment of migraine.

  • Aerie to Acquire Dry Eye Disease-Focused Pharma Avizorex
    Zacks

    Aerie to Acquire Dry Eye Disease-Focused Pharma Avizorex

    Aerie (AERI) will acquire Spanish ophthalmic pharmaceutical company, Avizorex Pharma, to add a mid-stage dry eye disease candidate to its pipeline.